Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/12/2017 12/13/2017 12/14/2017 12/15/2017 12/18/2017 Date
113.6(c) 113.54(c) 113.09(c) 115.76(c) 117.155 Last
1 611 091 1 873 365 1 624 438 3 412 397 548 936 Volume
+1.52% -0.05% -0.40% +2.36% +1.21% Change
More quotes
Financials ($)
Sales 2017 3 519 M
EBIT 2017 1 473 M
Net income 2017 528 M
Debt 2017 1 307 M
Yield 2017 -
Sales 2018 4 090 M
EBIT 2018 1 926 M
Net income 2018 998 M
Finance 2018 365 M
Yield 2018 -
P/E ratio 2017 48,72
P/E ratio 2018 25,93
EV / Sales2017 7,72x
EV / Sales2018 6,23x
Capitalization 25 862 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded... 
Sector
Pharmaceuticals
Calendar
02/01Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
12/13 ALEXION PHARMACEUTICALS : Results of Phase 1b 2 Dose Regimen Optimization Studie..
12/11 ALEXION PHARMACEUTICALS : Results of Phase 1b/2 Dose Regimen Optimization Studie..
12/11 ALEXION PHARMACEUTICALS : and Halozyme Enter License Agreement for ENHANZE Techn..
12/08 ALEXION PHARMACEUTICALS : Elliott Management seeks changes at Alexion - NYT
12/08 NASDAQ 100 MOVERS : Viab, alxn
12/08 S&P 500 MOVERS : Coo, alxn
12/08 MARKETS RIGHT NOW : Jobs, Brexit progress send stocks higher
12/07 NASDAQ 100 MOVERS : Ctrp, viab
12/07 S&P 500 MOVERS : Hrb, viab
11/27 ALEXION PHARMACEUTICALS : to Present at the Citi 2017 Global Healthcare Conferen..
More news
Sector news : Biopharmaceuticals
04:14p TSX up in broad rally; banks, energy stocks, Valeant lead
03:47p TEVA PHARMACEUTICAL INDUSTRIES : Union says workers at Israeli drugs firm Teva t..
03:47p TEVA PHARMACEUTICAL INDUSTRIES : Union says workers at Israeli drugs firm Teva t..
01:42p GLAXOSMITHKLINE : boosts stake in Saudi Arabia unit
12:13p Teva Pharm woes seen denting Israeli exports, economic growth
More sector news : Biopharmaceuticals
News from SeekingAlpha
08:36a Premarket analyst action - healthcare
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/13 ARGENX : This ASH Winner Has Further Upside Ahead
12/11 BIOTECH FORUM DAILY DIGEST : Revisiting Neos Therapeutics
12/11 Game Plan For The Week - Cramer's Mad Money (12/8/17)
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 163 $
Spread / Average Target 41%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Julie O'Neill Executive Vice President-Global Operations
Paul J. Clancy Chief Financial Officer
John J. Orloff Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS-5.39%25 862
BIOGEN25.49%69 352
CSL LIMITED39.46%48 543
GRIFOLS SA28.26%17 812
BIOMARIN PHARMACEUTICAL12.29%16 336
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%7 011